Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

National Healthcare (NHC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for National Healthcare (NHC) over the last 17 years, with Q3 2025 value amounting to $130.6 million.

  • National Healthcare's Cash & Equivalents rose 5403.09% to $130.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.6 million, marking a year-over-year increase of 5403.09%. This contributed to the annual value of $76.1 million for FY2024, which is 2890.94% down from last year.
  • As of Q3 2025, National Healthcare's Cash & Equivalents stood at $130.6 million, which was up 5403.09% from $111.0 million recorded in Q2 2025.
  • National Healthcare's Cash & Equivalents' 5-year high stood at $136.2 million during Q2 2024, with a 5-year trough of $44.5 million in Q3 2022.
  • In the last 5 years, National Healthcare's Cash & Equivalents had a median value of $94.0 million in 2024 and averaged $93.7 million.
  • As far as peak fluctuations go, National Healthcare's Cash & Equivalents plummeted by 6041.77% in 2022, and later surged by 12533.53% in 2023.
  • Quarter analysis of 5 years shows National Healthcare's Cash & Equivalents stood at $107.6 million in 2021, then tumbled by 45.48% to $58.7 million in 2022, then soared by 82.51% to $107.1 million in 2023, then decreased by 28.91% to $76.1 million in 2024, then surged by 71.61% to $130.6 million in 2025.
  • Its Cash & Equivalents was $130.6 million in Q3 2025, compared to $111.0 million in Q2 2025 and $90.4 million in Q1 2025.